REPLIGEN CORP (RGEN) Stock Fundamental Analysis
USA - NASDAQ:RGEN - US7599161095 - Common Stock
152.37 USD
+1.81 (+1.2%)
152.37 USD
0 (0%)
RGEN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. RGEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
In the past year RGEN had a positive cash flow from operations.
Of the past 5 years RGEN 4 years were profitable.
Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.06%, RGEN is in the better half of the industry, outperforming 68.97% of the companies in the same industry.
The Return On Equity of RGEN (0.08%) is better than 70.69% of its industry peers.
With a Return On Invested Capital value of 1.05%, RGEN perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
RGEN had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 13.56%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
RGEN has a better Profit Margin (0.25%) than 68.97% of its industry peers.
The Operating Margin of RGEN (6.58%) is better than 62.07% of its industry peers.
In the last couple of years the Operating Margin of RGEN has declined.
RGEN has a Gross Margin of 51.59%. This is comparable to the rest of the industry: RGEN outperforms 56.90% of its industry peers.
In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
The number of shares outstanding for RGEN has been increased compared to 1 year ago.
Compared to 5 years ago, RGEN has more shares outstanding
RGEN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.02 indicates that RGEN is not in any danger for bankruptcy at the moment.
The Altman-Z score of RGEN (7.02) is better than 87.93% of its industry peers.
RGEN has a debt to FCF ratio of 5.05. This is a neutral value as RGEN would need 5.05 years to pay back of all of its debts.
RGEN has a better Debt to FCF ratio (5.05) than 70.69% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
RGEN has a Debt to Equity ratio of 0.26. This is comparable to the rest of the industry: RGEN outperforms 51.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.02 |
ROIC/WACC0.11
WACC9.93%
2.3 Liquidity
A Current Ratio of 8.36 indicates that RGEN has no problem at all paying its short term obligations.
The Current ratio of RGEN (8.36) is better than 89.66% of its industry peers.
RGEN has a Quick Ratio of 7.14. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.14, RGEN belongs to the best of the industry, outperforming 89.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.17% over the past year.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
RGEN shows a decrease in Revenue. In the last year, the revenue decreased by -8.54%.
The Revenue has been growing by 18.62% on average over the past years. This is quite good.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.53% on average per year.
Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.90% on average per year.
EPS Next Y15.05%
EPS Next 2Y20.45%
EPS Next 3Y23%
EPS Next 5Y25.53%
Revenue Next Year15.25%
Revenue Next 2Y13.99%
Revenue Next 3Y14.29%
Revenue Next 5Y15.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 91.79, which means the current valuation is very expensive for RGEN.
RGEN's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of RGEN to the average of the S&P500 Index (25.89), we can say RGEN is valued expensively.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 70.97.
RGEN's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 34.59. RGEN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 91.79 | ||
| Fwd PE | 70.97 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 80.51 | ||
| EV/EBITDA | 75.35 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
RGEN's earnings are expected to grow with 23.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.1
PEG (5Y)12.92
EPS Next 2Y20.45%
EPS Next 3Y23%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
152.37
+1.81 (+1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners98.43%
Inst Owner Change17.02%
Ins Owners0.5%
Ins Owner Change-7.68%
Market Cap8.57B
Revenue(TTM)707.89M
Net Income(TTM)1.74M
Analysts80.71
Price Target181.69 (19.24%)
Short Float %6.44%
Short Ratio3.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)0.06%
PT rev (3m)-1.05%
EPS NQ rev (1m)-11.77%
EPS NQ rev (3m)-10.34%
EPS NY rev (1m)-0.74%
EPS NY rev (3m)-0.64%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)0.63%
Revenue NY rev (3m)2.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 91.79 | ||
| Fwd PE | 70.97 | ||
| P/S | 12.11 | ||
| P/FCF | 80.51 | ||
| P/OCF | 65.49 | ||
| P/B | 4.12 | ||
| P/tB | 14.91 | ||
| EV/EBITDA | 75.35 |
EPS(TTM)1.66
EY1.09%
EPS(NY)2.15
Fwd EY1.41%
FCF(TTM)1.89
FCFY1.24%
OCF(TTM)2.33
OCFY1.53%
SpS12.58
BVpS37.03
TBVpS10.22
PEG (NY)6.1
PEG (5Y)12.92
Graham Number37.19
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROCE | 1.67% | ||
| ROIC | 1.05% | ||
| ROICexc | 1.43% | ||
| ROICexgc | 5.46% | ||
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% | ||
| FCFM | 15.04% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 37.9% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.95% | ||
| Profit Quality | 6126.58% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 | ||
| Altman-Z | 7.02 |
F-Score6
WACC9.93%
ROIC/WACC0.11
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y15.05%
EPS Next 2Y20.45%
EPS Next 3Y23%
EPS Next 5Y25.53%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.25%
Revenue Next 2Y13.99%
Revenue Next 3Y14.29%
Revenue Next 5Y15.9%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year75.45%
EBIT Next 3Y40.62%
EBIT Next 5Y36%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status of REPLIGEN CORP (RGEN) stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the valuation of REPLIGEN CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 91.79 and the Price/Book (PB) ratio is 4.12.
Can you provide the expected EPS growth for RGEN stock?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 15.05% in the next year.